US-based leading molecular diagnostics company, Cepheid Inc. has unveiled its newest configuration in the GeneXpert family of systems, the GeneXpert Edge.
The company also announced its ‘Make in India’ initiative by announcing plans to establish their manufacturing footprint in the country for Xpert MTB/RIF test cartridges which run on the GeneXpert System.
More than 1,200 Cepheid’s GeneXpert Systems have been installed in the last 2 years at various Revised National Tuberculosis Control Program (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD). The GeneXpert Edge is expected to be available in India later this year.
The GeneXpert Edge is a portable, easy-to-use system, developed specifically for near-patient testing, to help support a one visit test-and-treat approach. With almost 17,000 systems in 182 countries, the GeneXpert System is the world’s most popular molecular diagnostics system. Its modular configuration makes it the most scalable platform available, delivering the ability to process from one to eighty tests simultaneously — enabling accurate, fast, and cost-effective test results in both lower volume point-of-care settings and higher volume reference laboratories.
Unveiling the GeneXpert Edge, Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid said, “The published data point out that Tuberculosis leads to over 400,000 deaths in India every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. Cepheid recognizes the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication.
“Our ‘Make in India’ plans are a testimony to our commitment towards supporting the Indian Government’s vision of TB eradication by 2025. With this announcement, we aim to establish a manufacturing footprint for Xpert MTB/RIF test cartridges, thus bringing our global expertise in TB diagnostics to India. Today, we also unveil our latest system innovation, the GeneXpert Edge, which further demonstrates our resolve to participate in India’s fight against TB,” Farrell said.
Jai Shankar Krishnan, President and CEO, India and Southeast Asia, Danaher said, “Cepheid brings cutting-edge technology and innovation to the molecular diagnostics platform. The launch of the GeneXpert Edge underscores our commitment to localization and to the eradication of TB in our country.”
Cepheid’s Xpert MTB/RIF test can simultaneously detect tuberculosis (MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in two hours. Xpert MTB/RIF tests have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. With unprecedented sensitivity for detecting MTB, even in smear negative, culture positive specimens Xpert MTB/RIF provides on-demand results enabling physicians to treat their patients rapidly and effectively.